Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Lesion of the subiculum reduces the spread of amyloid beta pathology to interconnected brain regions in a mouse model of Alzheimer's disease.

George S, Rönnbäck A, Gouras GK, Petit GH, Grueninger F, Winblad B, Graff C, Brundin P.

Acta Neuropathol Commun. 2014 Feb 11;2:17. doi: 10.1186/2051-5960-2-17.

2.

Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions.

Rönnbäck A, Sagelius H, Bergstedt KD, Näslund J, Westermark GT, Winblad B, Graff C.

Neurobiol Aging. 2012 Apr;33(4):831.e11-9. doi: 10.1016/j.neurobiolaging.2011.07.012. Epub 2011 Aug 31.

PMID:
21880397
3.

Early neuronal loss and axonal/presynaptic damage is associated with accelerated amyloid-β accumulation in AβPP/PS1 Alzheimer's disease mice subiculum.

Trujillo-Estrada L, Dávila JC, Sánchez-Mejias E, Sánchez-Varo R, Gomez-Arboledas A, Vizuete M, Vitorica J, Gutiérrez A.

J Alzheimers Dis. 2014;42(2):521-41. doi: 10.3233/JAD-140495.

PMID:
24927710
4.

Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer's disease.

Kukreja L, Kujoth GC, Prolla TA, Van Leuven F, Vassar R.

Mol Neurodegener. 2014 May 2;9:16. doi: 10.1186/1750-1326-9-16.

5.
6.

Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss.

Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M, Mann DM, Hyman BT, Iwatsubo T.

Am J Pathol. 2000 Jul;157(1):331-9. Erratum in: Am J Pathol 2000 Oct;157(4):1413.

7.

Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ.

J Neuroinflammation. 2010 Mar 8;7:17. doi: 10.1186/1742-2094-7-17.

8.
9.

Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.

Sadleir KR, Eimer WA, Kaufman RJ, Osten P, Vassar R.

PLoS One. 2014 Jul 3;9(7):e101643. doi: 10.1371/journal.pone.0101643. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e110914.

10.

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E.

J Neurosci Res. 2006 May 15;83(7):1252-61.

PMID:
16511867
11.

X11alpha haploinsufficiency enhances Abeta amyloid deposition in Alzheimer's disease transgenic mice.

Saluja I, Paulson H, Gupta A, Turner RS.

Neurobiol Dis. 2009 Oct;36(1):162-8. doi: 10.1016/j.nbd.2009.07.006. Epub 2009 Jul 23.

12.

Reduction of β-amyloid accumulation by reticulon 3 in transgenic mice.

Araki W, Oda A, Motoki K, Hattori K, Itoh M, Yuasa S, Konishi Y, Shin RW, Tamaoka A, Ogino K.

Curr Alzheimer Res. 2013 Feb;10(2):135-42.

PMID:
22742855
13.

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA.

J Neural Transm (Vienna). 2010 Jan;117(1):85-96. doi: 10.1007/s00702-009-0314-x. Epub 2009 Oct 13.

14.

Intracellular amyloid-β accumulation in calcium-binding protein-deficient neurons leads to amyloid-β plaque formation in animal model of Alzheimer's disease.

Moon M, Hong HS, Nam DW, Baik SH, Song H, Kook SY, Kim YS, Lee J, Mook-Jung I.

J Alzheimers Dis. 2012;29(3):615-28. doi: 10.3233/JAD-2011-111778.

PMID:
22269161
15.

The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.

Kalimo H, Lalowski M, Bogdanovic N, Philipson O, Bird TD, Nochlin D, Schellenberg GD, Brundin R, Olofsson T, Soliymani R, Baumann M, Wirths O, Bayer TA, Nilsson LN, Basun H, Lannfelt L, Ingelsson M.

Acta Neuropathol Commun. 2013 Sep 10;1:60. doi: 10.1186/2051-5960-1-60.

16.

Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice.

Devi L, Ohno M.

Neurobiol Dis. 2012 Jan;45(1):417-24. doi: 10.1016/j.nbd.2011.09.001. Epub 2011 Sep 13.

17.

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models.

Reinert J, Richard BC, Klafki HW, Friedrich B, Bayer TA, Wiltfang J, Kovacs GG, Ingelsson M, Lannfelt L, Paetau A, Bergquist J, Wirths O.

Acta Neuropathol Commun. 2016 Mar 8;4:24. doi: 10.1186/s40478-016-0294-7.

18.

Mitochondrial dysfunction in a transgenic mouse model expressing human amyloid precursor protein (APP) with the Arctic mutation.

Rönnbäck A, Pavlov PF, Mansory M, Gonze P, Marlière N, Winblad B, Graff C, Behbahani H.

J Neurochem. 2016 Feb;136(3):497-502. doi: 10.1111/jnc.13410. Epub 2015 Nov 19.

19.

Impact of CRFR1 Ablation on Amyloid-β Production and Accumulation in a Mouse Model of Alzheimer's Disease.

Campbell SN, Zhang C, Roe AD, Lee N, Lao KU, Monte L, Donohue MC, Rissman RA.

J Alzheimers Dis. 2015;45(4):1175-84. doi: 10.3233/JAD-142844.

20.

Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition.

Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW.

J Neuroinflammation. 2014 Jun 19;11:111. doi: 10.1186/1742-2094-11-111.

Supplemental Content

Support Center